[
    {
        "outcome_uid": "78d8a0b8",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disease activity (follow up: range 6 months to 2 years; assessed with: ACR 20)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "fbec7a1c",
            "07165ed3",
            "7ef8f3ac",
            "7321b644",
            "54351bf3",
            "72824791",
            "ccd87125",
            "2140c6ee",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "TNFi+MTX": "1414/2051 (68.9%)",
                    "MTX monotherapy": "1134/2094 (54.2%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.25 (1.19 to 1.31)",
                    "Absolute Effect (95% CI)": "135 more per 1,000 (from 103 more to 168 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "e6b6d583",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disease activity (follow up: 1 year; assessed with: ACR 50)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "7321b644",
            "54351bf3",
            "72824791",
            "2140c6ee",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "TNFi+MTX": "559/974 (57.4%)",
                    "MTX monotherapy": "363/881 (41.2%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.42 (1.29 to 1.56)",
                    "Absolute Effect (95% CI)": "173 more per 1,000 (from 119 more to 231 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "ce479e4f",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disease activity (follow up: range 6 months to 2 years; assessed with: ACR 70)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "fbec7a1c",
            "07165ed3",
            "7ef8f3ac",
            "7321b644",
            "54351bf3",
            "72824791",
            "ccd87125",
            "2140c6ee",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": "I2=17%"
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "TNFi+MTX": "733/2051 (35.7%)",
                    "MTX monotherapy": "401/2094 (19.1%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.74 (1.55 to 1.96)",
                    "Absolute Effect (95% CI)": "142 more per 1,000 (from 105 more to 184 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "0f903a27",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disease activity (follow up: range 6 months to 1 year; assessed with: DAS28-ESR/CRP)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "07165ed3",
            "7321b644",
            "72824791",
            "ccd87125",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": "According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "TNFi+MTX": "1133",
                    "MTX monotherapy": "1200"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "SMD 0.39 lower (0.47 lower to 0.31 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "a90be394",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Remission (follow up: range 6 months to 2 years; assessed with: DAS28-ESR remission <2.6)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "fbec7a1c",
            "07165ed3",
            "7ef8f3ac",
            "7321b644",
            "54351bf3",
            "2140c6ee",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "TNFi+MTX": "662/1743 (38.0%)",
                    "MTX monotherapy": "353/1667 (21.2%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.80 (1.62 to 2.01)",
                    "Absolute Effect (95% CI)": "169 more per 1,000 (from 131 more to 214 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "880893eb",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Radiographic progression (follow up: range 6 months to 1 year; assessed with: mTSS)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "fbec7a1c",
            "54351bf3",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious inconsistency. I2=90%."
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi+MTX": "782",
                    "MTX monotherapy": "702"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 1.94 lower (3.61 lower to 0.28 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "3f0cd584",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Fatigue (follow up: range 1 year to 2 years; assessed with: VAS-F or FACIT-F)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "c45ae481",
            "b6dac38c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "SERIOUS",
                    "rationales": "I2=55%"
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Rated down by one level for imprecision, as CI includes both values suggesting benefits and values suggesting no effect. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi+MTX": "530",
                    "MTX monotherapy": "520"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "SMD 0.15 higher (0.03 higher to 0.28 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "dba7e264",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Pain (follow up: range 1 year to 2 years; assessed with: VAS pain (0-100))",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "c45ae481",
            "b6dac38c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious inconsistency. I2=85%"
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi+MTX": "530",
                    "MTX monotherapy": "519"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 4.66 lower (6.93 lower to 2.39 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "36d3e6c6",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disability (follow up: range 6 months to 24 months; assessed with: HAQ-DI)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "07165ed3",
            "7321b644",
            "72824791",
            "ccd87125",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious inconsistency. I2=92%"
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Rated down by one level for imprecision, as CI includes both values suggesting benefits and values suggesting no effect. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "TNFi+MTX": "1135",
                    "MTX monotherapy": "1119"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n2. The studies PREMIER, COMET and ASPIRE found that the RR of improvement in HAQ-DI (\u22650.22 change from baseline) at 1-2 years was 1.05 (95%CI 0.87 to 1.28), absolute risk increase 36 more per 1000 (95%CI 94 fewer to 201 more).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.19 lower (0.25 lower to 0.14 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "9165f76f",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 PCS)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "cbcb86ec",
            "c45ae481",
            "b6dac38c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious inconsistency. I2=88%"
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi+MTX": "880",
                    "MTX monotherapy": "792"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 1.39 higher (1.42 lower to 4.2 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "84f30189",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 MCS)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "c45ae481",
            "b6dac38c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "TNFi+MTX": "521",
                    "MTX monotherapy": "510"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.15 lower (1.35 lower to 1.04 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "9bb728fc",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Withdrawal due to lack of efficacy (follow up: range 1 year to 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "07165ed3",
            "7321b644",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": "I2=42%"
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "TNFi+MTX": "33/716 (4.6%)",
                    "MTX monotherapy": "99/628 (15.8%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.32 (0.19 to 0.52)",
                    "Absolute Effect (95% CI)": "107 fewer per 1,000 (from 128 fewer to 76 fewer)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "7adc5bbc",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Withdrawal due to adverse events (follow up: range 6 months to 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "07165ed3",
            "7ef8f3ac",
            "7321b644",
            "2140c6ee",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "TNFi+MTX": "109/1389 (7.8%)",
                    "MTX monotherapy": "53/1305 (4.1%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.88 (1.36 to 2.59)",
                    "Absolute Effect (95% CI)": "36 more per 1,000 (from 15 more to 65 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "82163f18",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Serious adverse events (follow up: range 6 months to 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "07165ed3",
            "7ef8f3ac",
            "7321b644",
            "54351bf3",
            "72824791",
            "2140c6ee",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi+MTX": "235/1677 (14.0%)",
                    "MTX monotherapy": "188/1580 (11.9%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.17 (0.99 to 1.40)",
                    "Absolute Effect (95% CI)": "20 more per 1,000 (from 1 fewer to 48 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "e9b48a35",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Cardiovascular disease (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "7321b644",
            "54351bf3",
            "cbcb86ec"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi+MTX": "4/721 (0.6%)",
                    "MTX monotherapy": "6/632 (0.9%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.62 (0.17 to 2.21)",
                    "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 8 fewer to 11 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "ac069dd3",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Malignancy (follow up: range 1 year to 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "7ef8f3ac",
            "54351bf3"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi+MTX": "6/542 (1.1%)",
                    "MTX monotherapy": "8/525 (1.5%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.74 (0.25 to 2.14)",
                    "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 11 fewer to 17 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "b588c564",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Death (follow up: range 6 months to 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "07165ed3",
            "7ef8f3ac",
            "2140c6ee",
            "cbcb86ec",
            "6a7646d3"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi+MTX": "10/1587 (0.6%)",
                    "MTX monotherapy": "4/1493 (0.3%)"
                },
                "Annotation": {
                    "data": "1. TNFis includes Etanercept, Adalimumab, Certolizumab, Golimumab and Infliximab.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.85 (0.57 to 6.00)",
                    "Absolute Effect (95% CI)": "2 more per 1,000 (from 1 fewer to 13 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "2aaca0e3",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Malignancy (from SRs on harms)",
        "related_paper_list": [
            "45b0286b"
        ],
        "assessment_results": {
            "GRADE": {
                "result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=6, n=1890) comparing any TNFi + csDMARD vs csDMARD among RA showed that for Cancer, the result was RR=0.85 (0.30-2.4) at 2 years and RR=1.3 (0.77-2.1) at all time points combined (6 months, 1 year, 2 years, 2.5 years, RCT=29, n=11144) ",
                "Study design": "Systematic Review"
            }
        }
    }
]